北陆药业(300016.SZ)获得碘美普尔注射液药品注册证书

Core Viewpoint - Northland Pharmaceutical has received approval from the National Medical Products Administration for the iodine-based contrast agent, Iodine Meperidine Injection, which is expected to drive significant sales growth in the coming years [1] Company Summary - Northland Pharmaceutical has announced the approval of Iodine Meperidine Injection, developed by Italy's Bracco, which is a non-ionic monomer X-ray contrast agent [1] - The product exhibits superior physicochemical properties, having the lowest osmotic pressure and lower viscosity compared to similar agents at the same concentration, and does not require the addition of chelating agents [1] - The indications for Iodine Meperidine Injection include intravenous urography, CT scans, conventional angiography, and various other imaging procedures for both adults and children [1] Industry Summary - Iodine Meperidine Injection has been included in the National Medical Insurance Category B directory, indicating its significance in the healthcare market [1] - According to data from Minet, sales in China's three major terminal markets have been growing at a double-digit rate, with projected sales exceeding 1.1 billion yuan in 2024, representing a year-on-year growth of approximately 32% [1] - In the first quarter of 2025, sales are expected to surpass 300 million yuan, with a year-on-year growth of about 39% [1]